Nyxoah SA (EBR:NYXH)

Belgium flag Belgium · Delayed Price · Currency is EUR
3.995
+0.055 (1.40%)
At close: Feb 9, 2026
Market Cap171.89M -54.5%
Revenue (ttm)5.64M +11.0%
Net Income-83.72M
EPS-2.24
Shares Out43.03M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,405
Average Volume60,025
Open4.000
Previous Close3.940
Day's Range3.980 - 4.040
52-Week Range3.840 - 11.150
Beta0.65
RSI43.47
Earnings DateMar 19, 2026

About Nyxoah

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]

Sector Healthcare
Founded 2009
Employees 184
Stock Exchange Euronext Brussels
Ticker Symbol NYXH
Full Company Profile

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.

Financial Statements